AIDS Therapies

NIH Uses Bioject's Needle-Free Injection System For DNA AIDS Vaccine Study

Published in Vaccine Weekly, November 14th, 2001

The Biojector 2000 (B-2000) has been chosen by the Dale and Betty Bumpers Vaccine Research Center (VRC) as the delivery device for its first AIDS vaccine in human clinical testing. The B-2000 was developed by Bioject Medical Technologies (BJCT), which specializes in needle-free drug delivery systems. The VRC is part of the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH).

Participants will be given three 1 ml intramuscular injections in the upper arm with the B-2000 system, the only needle-free device cleared by the FDA to give intramuscular injections.

The VRC is described as a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry